Jemperli GlaxoSmithKline Australia Pty Ltd
Product name
Jemperli
Accepted date
Apr-2024
Active ingredients
dostarlimab
Proposed indication
For the treatment of endometrial cancer.
Application type
C (new indication)
Publication date
Apr-2024